All
FDA Approves Tasigna for Pediatric CML
March 22nd 2018Tasigna (nilotinib) was granted Food and Drug Administration (FDA) approval, to be used in the first- and second-line setting for pediatric patients 1 year old or older who have Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
FDA Approves Adcetris Combination for Hodgkin Lymphoma
March 20th 2018Adcetris (brentuximab vedotin), in combination with chemotherapy, was granted approval by the Food and Drug Administration (FDA) as a frontline treatment option for patients with stage 3 or 4 classical Hodgkin lymphoma, according to the manufacturer of the drug, Seattle Genetics.
Xtandi Granted Priority Review for Prostate Cancer Treatment
March 20th 2018The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.
Early Trial Shows 'Smart Bomb' Virus Extends Survival in Patients With Glioblastoma
March 19th 2018Findings from an early phase clinical trial that used a so-called “smart bomb” virus — which was altered to attack tumor cells rather than normal cells — appeared to show promise in this area.